Ingevity Corporation
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-90.9% vs price
Base Case (Median)
-74.4% vs price
Bull Case (75th pct.)
-53.5% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-166.44 | -333.9% | High (40%) |
| PE Comparable | $26.04 | -63.4% | Medium (25%) |
| Growth Trajectory DCF | $35.47 | -50.2% | Medium (20%) |
| Graham Number | $5.21 | -92.7% | Medium (30%) |
| EV/EBITDA | $10.33 | -85.5% | Medium (20%) |
| EV/FCF | $85.58 | 20.3% | Medium (20%) |
Based on 6 out of 8 methods, NGVT appears overvalued at the current price of $71.16. The base case fair value of $18.19 implies 74.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.